(Adnkronos) - "E’ importante che ci siano dei centri di riferimento. Le persone devono poter trovare, nella loro realtà territoriale chi è in grado di fare una diagnosi tempestiva e accurata”. A dirlo è Mario Alberto Battaglia, socio fondatore e Vice Presidente di Ainmo, Associazione italiana neuromielite ottica e direttore generale di Aism, Associazione italiana sclerosi multipla, in occasione dell'annuncio del rimborso di ravulizumab per il trattamento degli adulti affetti da disturbo dello spettro della neuromielite ottica (Nmosd) positivi all'anticorpo anti-aquaporina-4 (Aqp4) (Ab+). Si tratta del primo inibitore del complemento C5 a lunga durata d’azione per il trattamento di questa malattia rara.
Category
🗞
NewsTranscript
00:00The Italian Association of Multiple Sclerosis has chosen to give life to the Italian Neuromedical Association,
00:10obviously together with people with optical neuromedical disease,
00:14because it is right that there is a reference association for each disease
00:19and there are people who are primarily protagonists of their choices, but also of the defense of their rights.
00:28This means, of course, with the three key words that must always characterize an association,
00:35people, research and rights.
00:38It is important that there are reference centers,
00:43because people must be able to find in their territorial reality
00:48who is able to make an accurate tempestuous diagnosis,
00:53a diagnosis that does not stop as a first step,
00:58because in reality there is a monitoring, a cure that must continue,
01:03up to the evaluations through the center, through the territorial network,
01:09of all those needs that must find answers for the person,
01:14the possibility of living their own life in addition to the disease.
01:17Surely drugs today are a reality, as for other diseases,
01:23they are innovative drugs, they can bring us close to 100% of the block of the evolution of the disease,
01:31which in the past was not possible,
01:34and therefore the right to have these cures is fundamental,
01:38the right to have the possibility to look to the future,
01:42because these drugs can allow to block the evolution of the disease.
01:47www.cdc.gc.ca